Urothelial carcinoma accounts for the vast majority of bladder cancers and presents along a continuum from non-muscle-invasive lesions to muscle-invasive and metastatic disease. Non-muscle-invasive ...

LAS VEGAS, Aug 6, 2025 /PRNewswire/ -- DelveInsight's Urothelial Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, urothelial carcinoma emerging ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus pembrolizumab therapy." First authors Elias Antoine Karam of the Gustave Roussy and ...

The Bladder Cancer Treatment Market was valued at USD 5.13 Billion in 2025 and is projected to expand at a 9.2% CAGR from ...

Please provide your email address to receive an email when new articles are posted on . Creation Healthcare analyzed 1,462 English language posts on X by 1,050 health care professionals. Health care ...

A manageable safety profile was observed across 2 expansion doses of the combination in urothelial cancer, consistent with known adverse effects of both drugs. The combination of the MAT2A inhibitor ...

Before the discovery of newer options and combinations, chemotherapy that included platinum medications like cisplatin or carboplatin was the first choice, says Christopher Wee, MD, a genitourinary ...

Treatment with disitamab vedotin and toripalimab improves survival regardless of cisplatin eligibility or HER2 expression level in the phase 3 RC48-C016 trial. Combining disitamab vedotin with ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer. Patients with high-risk muscle-invasive urothelial ...

Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with pelvic lymph node dissection has been the standard of care for muscle-invasive bladder cancer for decades. The advent of ...

They further applied two-sample Mendelian randomization (TSMR) analysis to examine genetic associations between prostate cancer and ten common secondary primary malignancies (SPMs). The study not only ...

As treatment options for metastatic urothelial carcinoma have diversified in recent years, the importance of patient-specific ...